Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of July 2025, specifically detailing a share repurchase executed on July 22, 2025. The transaction was conducted through Merrill Lynch International as part of an existing non-discretionary buyback agreement entered into on June 4, 2025.
Key Financial Metrics
The filing details the following specific metrics regarding the share repurchase activity:
- Shares Purchased (July 22, 2025): 506,734 ordinary shares.
- Price Range: Lowest price paid was 1,337.50 GBp; highest price paid was 1,359.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,347.53 GBp.
- Cumulative Buyback (Since June 4, 2025): 15,694,046 ordinary shares.
- Treasury Shares Held: 233,828,429 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,081,555,851 ordinary shares.
- Total Voting Rights: 4,081,555,851.
- Treasury Voting Rights Percentage: 5.73%.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares resulting from the July 22 transaction. The company confirms that the purchased shares are held as Treasury shares. No other material changes to the company's financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025.
Investor Verification Checklist
- Verify the total number of shares remaining in the buyback program authorization.
- Confirm the impact of the 5.73% treasury share holding on earnings per share (EPS) calculations.
- Review the referenced 2024 Form 20-F and 2025 Q1 Results for detailed risk factors and financial performance context.
- Monitor future 6-K filings for updates on the cumulative buyback volume and remaining program duration.